Product Image

Contributor Information

  • Name David Lane
  • Institute Cancer Research UK, London Research Institute: Clare Hall Laboratories
  • Primary citation Greaves. R. F (1988) Ph.D Thesis. University of London.

Tool Details

  • Tool name: Anti-p53 [Pab 240]
  • Clone: Pab 240
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Chicken ; Mammalian
  • Host: Mouse
  • Cancer type: Broadly Applicable
  • Molecular weight of the target: 53 kDa
  • Application: FACS ; IHC ; IF ; IP ; WB
  • Strain: Balb/c
  • Description: This monoclonal antibody reacts specifically with mutated p53 at an epitope conserved across species and normally hidden within the protein structure in non-mutant forms. Anti-p53 Pab 240 was created further understand the biochemical role of p53 in cancers and the precise effects of mutation. Anti-p53 (Pab 240) antibody recognises an evolutionarily conserved epitope upon p53 hidden within the normal protein structure, however, it does not bind to immunoprecipitated wild-type p53. This antibody recognises an epitope that is structurally elusive when p53 is in a wild-type conformation but becomes accessible upon denaturation or through mutational conformations where point mutations within the TP53 gene alter the conformational structure of the protein. Pab 240 recognises an epitope at aa 211-217 in the DNA binding region of p53.

    Alternative p53 antibodies that also detect mutant p53 include DO-11 (Cat. #153402) and DO-12 (Cat. #153403). To detect wild-type p53 Pab 246 (Cat. #151412) has been used.
  • Immunogen: p53-b-galactosidase fusion protein containing p53 sequence from amino acids 14-389 (derived from the pSV53C p53 cDNA clone)
  • Immunogen UniProt ID: P04637
  • Isotype: IgG1 kappa
  • Research area: Apoptosis and autophagy; Cancer; Cell biology; Genetics
  • Myeloma used: Sp2/0-Ag14

  • For Research Use Only

Target Details

  • Target: p53
  • Target molecular weight: 53 kDa
  • Target background: p53 is a stress-regulated transcription factor that regulates cell cycle arrest and was first identified as an SV40 large T antigen-binding protein. p53 is the most common genetic mutational event so far identified in human cancers, with the gene present on the short arm of chromosome 17 a frequent site of allele loss in common cancers. The structure of p53 comprises an N-terminal transactivation domain, a central DNA-binding domain, an oligomerisation domain, and a C-terminal regulatory domain. p53 is a tumour suppressor which upregulates growth arrest and apoptosis-related genes in response to stress signals, thereby influencing programmed cell death, cell differentiation, and cell cycle control mechanisms. Twelve isoforms of p53 have been described. Depending on the location of the epitope, antibodies may detect different isoforms of p53. Mutations to p53 can cause conformational changes that expose different epitopes. Pab 240 detects mutant forms of p53.

Application Details

  • Application: FACS ; IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20°C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-DNA [m165-60]

#157827
Product Image

Anti-Myelin Basic Protein (region Thr98) [98/P12]

#153644
Product Image

Anti-phospho-HSP90 [GDD8.2]

#160749

References

  • •  Renzi et al. 2019. PLoS One. 14(4):e0215621. PMID: 30998743.
  • •  Diaz Osterman et al. 2019. Elife. 8:. PMID: 31478830.
  • •  Fekry et al. 2018. Nat Commun. 9(1):4149. PMID: 30297838.
  • •  Katz et al. 2018. Genes Dev. 32(5-6):430-447. PMID: 29549180.
  • •  Chen et al. 2017. Br J Pharmacol. 174(23):4345-4361. PMID: 28910492.
  • •  Ilhan et al. 2016. J Vet Diagn Invest. :. PMID: 27016721.
  • •  Jakobsen et al. 2015. J Extracell Vesicles. 4:26659. PMID: 25735706.
  • •  Pan et al. 2009. EMBO J. 28(22):3500-13. PMID: 19745809.
  • •  Said et al. 1992. Am J Pathol. 141(6):1343-8. PMID: 1466398.
  • •  Walker et al. 1991. J Pathol. 165(3):203-11. PMID: 1684809.
  • •  Brtek et al. 1991. Oncogene. 6(9):1699-703. PMID: 1923535.
  • •  Gannon et al. 1990. EMBO J. 9(5):1595-602. PMID: 1691710.
  • •  Iggo et al. 1990. Lancet. 335(8691):675-9. PMID: 1969059.
  • •  Greaves. R. F (1988) Ph.D Thesis. University of London.